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ABSTRACT
Background: Radial access is effective in reducing bleeding 
complications in percutaneous coronary interventions (PCI). 
In acute coronary syndromes (ACS), the crossover from low 
molecular weight to unfractioned heparin increases the risk 
of bleeding after transfemoral PCI. The aim of this study 
was to evaluate the incidence of bleeding in patients with 
ACS undergoing PCI using the radial approach according 
to the occurrence or not of crossover of heparin therapy. 
Methods: Observational study of patients with ACS under­
going PCI using the radial access, divided into groups: A 
(with crossover) and B (without crossover). Bleeding events 
were classified according to GUSTO criteria; EASY criteria 
were used for bleeding events in the radial access. Results: 
We included 140 consecutive patients, 74 in group A and 
66 in group B, with mean age of 59.7 ± 9.4 years, 72.8% 
were male, and 21.4% diabetic. There were six cases 
of bleeding complications (4.3%), and two (1.4%) were 
classified by GUSTO as moderate (one digestive bleeding 
and one femoral bleeding after intraaortic balloon pump), 
and four (2.9%) were classified as mild (hematomas with 
diameter ≤ 5 cm). In the comparison between groups, mod­
erate bleeding occurred in 1.3% in group A and 1.5% in 
group B (P = 0.49) and mild bleedings in 2.7% and 3.1% 
in groups A and B, respectively (P = 0.37). Conclusions: 
In this cohort of patients with ACS undergoing PCI using 
the radial access, a low incidence of bleeding events was 
observed, and most of these bleeding complications resulted 
from small hematomas of the access route. Crossover of 
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RESUMO
Crossover da Terapia com Heparina e Risco de 
Sangramento na Intervenção Coronária Percutânea 
Transradial na Síndrome Coronária Aguda
Introdução: A utilização da via radial tem reconhecida eficácia 
em reduzir complicações hemorrágicas na intervenção coronária 
percutânea (ICP). Nas síndromes coronárias agudas (SCAs), o 
crossover (transição) entre a heparina de baixo peso molecular 
e a heparina não­fracionada aumenta o risco hemorrágico após 
ICP por via femoral. O objetivo deste estudo foi comparar a 
incidência de sangramentos em pacientes com SCA submeti 
dos a ICP por via radial de acordo com a ocorrência, ou 
não, do crossover da terapia com heparina. Métodos: Estudo 
observacional de pacientes com SCA submetidos a ICP por via 
radial, divididos em grupos A (no qual ocorreu crossover) e B 
(sem crossover). Os eventos hemorrágicos foram classificados 
conforme os critérios do GUSTO; para os sangramentos da 
via de acesso radial, foram utilizados os critérios do EASY. 
Resultados: Foram incluídos 140 pacientes consecutivos, 74 
pacientes no grupo A e 66 pacientes no grupo B, com média 
de idade de 59,7 ± 9,4 anos, 72,8% do sexo masculino e 
21,4% diabéticos. Ocorreram seis casos de complicações he­
morrágicas (4,3%), sendo duas (1,4%) classificadas pelo GUSTO 
como moderadas (uma hemorragia digestiva e um sangramento 
femoral após balão intra­aórtico) e quatro (2,9%), como leves 
(hematomas com diâmetro ≤ 5 cm). Na comparação entre 
os grupos, sangramentos moderados ocorreram em 1,3% no 
grupo A e em 1,5% no grupo B (P = 0,49) e sangramentos 
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DESCRIPTORS: Angioplasty. Radial artery. Hemorrhage
Procedures
In all patients who underwent the radial puncture 
technique to obtain access with hyperextension of the 
wrist and infiltration of 0.5 to 2 mL of 2% lidocaine, 
the radial artery was punctured 1 cm proximal to 
the styloid process of the radius using a needle with 
a 20/22­gauge JelcoTM polyethylene catheter and the 
Seldinger technique. After puncture, a 0.021­inch guide 
wire was introduced, followed by small skin incision 
with a #11 scalpel blade; then, a 6 F introducer was 
inserted (Terumo Glidesheath, Terumo Corporation – 
Tokyo, Japan). A solution containing 5,000 IU heparin 
sulfate was administered through the introducer to all 
patients undergoing procedures through radial approach, 
according to the service routine. This local hepariniza­
tion is performed in all patients to prevent thrombosis 
of the radial artery. After the end of the procedure, the 
introducer was immediately removed, and hemostasis 
was achieved using a manual compression dressing 
consisting of gauze and an elastic bandage or radial 
compression strap (TR BandTM, Terumo Corporation – 
Tokyo, Japan). Clinical examination of the puncture site, 
and radial pulse evaluation during hospitalization and 
at discharge were routinely performed.
After the antithrombotic drugs that were used before 
and during the PCI procedure were determined, two 
groups were defined according to the occurrence (group 
A) or not (group B) of crossover. Group A comprised 
patients who received full dose of low­molecular­weight 
heparin; the last dose was given 12 hours before PCI 
(enoxaparin 1 mg/kg, subcutaneously, every 12 hours; 
in case of creatinine clearance < 30 mL/min or 0.75 
mg/kg, subcutaneously every 12 hours in case of age 
> 75 years with no renal dysfunction). This group 
received unfractionated heparin in the catheterization 
lab and included not only patients who received 5,000 
IU of unfractionated heparin by introducer to prevent 
thrombosis of the radial artery, but also those who, in 
addition to the dose of unfractionated heparin received 
through the introducer, also received a complementary 
dose of unfractionated heparin intravenously (up to 100 
IU/kg or 70 IU/kg in cases receiving glycoprotein IIb/
IIIa) when undergoing ICP. Group B included patients 
who did not receive low molecular­weight heparin 
within the 12 hours prior to PCI and who received 
only unfractionated heparin as an antithrombotic agent 
for coronary angiography and PCI.
T he adverse impact of bleeding events after per­cutaneous coronary intervention (PCI) has been consistently demonstrated in several studies,1­3 and 
such events are equivalent to acute myocardial infarc­
tion (AMI) as a predictor of mortality in the short and 
middle term.4,5 Transradial PCI approach is currently 
one of the main strategies to reduce bleeding,6,7 as most 
observed bleeding events are associated with the femoral 
access route. It has been shown that the benefit of the 
transradial approach is even more marked in patients 
with acute coronary syndrome (ACS), considering the 
wider spectrum of antithrombotic drugs and higher risk 
of bleeding complications in these patients.8,9
A subanalysis of the Superior Yield of the New 
Strategy of Enoxaparin, Revascularization and Glyco­
protein IIb/IIIa Inhibitors (SYNERGY) study demonstrated 
that the crossover of heparin therapy (crossover or 
transition between low­molecular­weight heparin and 
unfractionated heparin) is associated with greater risk 
of bleeding after PCI using the femoral access route.10,11 
However, the potential risk of bleeding complications 
associated with the crossover of heparin therapy has 
not been investigated in patients undergoing transradial 
PCI approach. Thus, the primary objective of this study 
was to evaluate the incidence and cha racteristics of 
bleeding complications in patients with ACS undergo­
ing transradial PCI approach, according to the presence 
or absence of crossover between low­molecular­weight 
heparin and unfractionated heparin.
Methods
study design and population
This was a retrospective analysis of observational 
data from patients admitted with a diagnosis of ACS 
with or without ST­segment elevation who underwent 
coronary angiography and primary or ad hoc PCI via 
the transradial approach at Instituto Dante Pazzanese 
de Cardiologia (São Paulo, SP, Brazil). Cases that re­
quired changing of the vascular access from radial to 
femoral or those who were in cardiogenic shock were 
excluded. The clinical characteristics, procedures, and 
hospital outcomes had been prospectively collected 
since 2007, and made available in the database of the 
Department of Invasive Cardiology of the institution. 
All patients signed an informed consent prior to the 
PCI. The study was approved by the Research Ethics 
Committee of the hospital.
leves, em 2,7% e em 3,1% nos grupos A e B, respectivamente 
(P = 0,37). Conclusões: Nesta casuística de pacientes com 
SCA submetidos a ICP pela via radial, foi observada baixa 
incidência de sangramentos, sendo a maioria das complicações 
hemorrágicas decorrente de pequenos hematomas da via de 
acesso. O crossover da terapia com heparina não conferiu 
risco aumentado de sangramentos após ICP pela via radial.
DESCRITORES: Angioplastia. Artéria radial. Hemorragia.
Barbosa et al. 
Crossover of Heparin Therapy and Bleeding Risk in Transradial PCI 
Rev Bras Cardiol Invasiva. 
2012;20(4):392-7
394
The activated clotting time was not routinely 
monitored. All patients were taking acetylsalicylic acid 
(loading dose of 200 mg to 300 mg, followed by 100 
mg to 200 mg daily) and clopidogrel (loading dose of 
300 mg to 600 mg, followed by 75 mg daily). None 
of the patients included in the study used any other 
antiplatelet drugs during hospitalization.
definitions
Bleeding complications were evaluated as the pri­
mary endpoint of safety, using the criteria of the Global 
Utilization of Streptokinase and Tissue Plasminogen 
Activator for Occluded Coronary Arteries (GUSTO)12 
study and those of the Early Discharge after Transradial 
Stenting of Coronary Arteries (EASY) classification13 for 
the bleeding in the transradial access route (Table  1). 
All bleeding events at the radial puncture site or else­
where that occurred from the beginning of PCI until 
discharge were considered hemorrhagic complications.
Chronic renal failure was considered when the 
plasma creatinine at hospital admission >  1.4 mg/dL 
or creatinine clearance < 60 mL/ minute.
statistical Analysis 
For the descriptive data analysis, categorical variables 
were expressed as absolute frequencies and percen­
tages, and were compared using the chi­squared test or 
Fisher’s exact test. Continuous variables were expressed 
as the mean and standard deviation and compared 
using Student’s t-test. Groups A and B were compared 
with regard to baseline clinical characteristics; clinical 
presentation; occurrence of major adverse cardiac events 
(MACE), i.e., composite outcome of death, AMI, and 
stroke; and the incidence and severity of bleeding (with 
the bleeding specified as originating or not originating 
from the puncture site). A comparative analysis was 
also performed in patients from group A regarding the 
incidence of bleeding in cases that required or did not 
require intravenous unfractionated heparin complement. 
SPSS release 13.0 was used for the statistical analyses, 
and P < 0.05 was considered statistically significant.
Results
Between May 2008 and June 2010, 140 consecu­
tive patients admitted with a diagnosis of ACS with or 
without ST­segment elevation and submitted to primary 
or ad hoc PCI by transradial approach were included 
in this analysis. Among these patients, 102 (72.8%) 
were males, the mean age was 59.7 ± 9.4 years, and 
21.4% were diabetics. Group A consisted of 74 patients 
(52.9%), and group B consisted of 66 patients (47.1%). 
The mean length of hospitalization, which corresponded 
to the duration of patient follow­up, was 5.4 ± 2.2 days. 
The baseline characteristics and clinical presentations 
of patients are shown in Table 2. 
Among the patients in group A, 32 (43.2%) received 
only unfractionated heparin through the introducer, 
without a supplemental dose, and the remaining 42 
received an intravenous supplemental dose of unfrac­
tionated heparin. Glycoprotein IIb/IIIa inhibitors were 
administered to 37 patients (26.4%); 20 in group A and 
17 in group B (27% vs. 25.7%, respectively; P = 0.86). 
Procedural success (residual stenosis diameter 
> 30% in the final Thrombolysis in Myocardial Infarction 
Table 1 
Bleeding criteria according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator  
for Occluded Coronary Arteries (GUSTO) study and the Early Discharge after Transradial  
Stenting of Coronary Arteries (EASY) classification for hematoma at the puncture site
Definitions
Bleeding classification
Severe or life­threatening Intracranial hemorrhage or hemodynamic compromise requiring treatment
Moderate Need for blood transfusion
Mild Did not meet criteria for moderate or severe bleeding
Hematoma classification
Type I ≤ 5 cm of diameter
Type II ≤ 10 cm of diameter
Type III > 10 cm of diameter
Type IV Hematoma reaching beyond the elbow
Type V Any hematoma with ischemic hand injury
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[TIMI] flow 3) was achieved in 136 patients (Group A, 
97.3%; Group B, 96.9%; P  =  0.38).
The incidence of bleeding complications in the 
study population was 4.3% (six events). Two of these 
events (1.4%) were classified as moderate by the GUSTO 
criteria (one upper gastrointestinal hemorrha ge and 
bleeding in the femoral puncture site after use of an 
intra­aortic balloon; these cases received concomitant 
administration of glycoprotein IIb/IIIa). The four ad­
ditional bleeding events (2.9%) occurred at the radial 
puncture site and were defined as mild bleeding ac­
cording to GUSTO or type I according to the EASY 
study classification (hematomas with diameter < 5 cm). 
There were no differences between groups A and B 
regarding the occurrence of bleeding (Figure 1). In 
group A, there was no difference in the overall inci­
dence of bleeding among patients who received only 
unfractionated heparin through the radial introducer and 
those who required a supplemental intravenous dose of 
unfractionated heparin (3.1% and 4.7%, respectively; 
P = 0.72). No other complications related to the 
vascular puncture site, such as arteriovenous fistula, 
pseudoaneurysm, symptomatic radial artery thrombosis, 
or local infection were observed.
The rate of in­hospital MACE was similar between 
groups A and B (2.7% vs. 1.5%; P  =  0.39), and the 
incidence of isolated adverse outcomes was also similar 
between groups A and B (death, 1.4% vs. 1.5%; P = 
0.50; AMI, 1.4% vs. 0%; P = 0.52); no strokes were 
recorded.
discussion
In the authors’ experience, the routine use of 
transradial access in PCI is feasible, as demonstrated 
by the high rate of procedural success and safety of 
this access route. The low incidence of bleeding events 
due to the use of transradial access makes it an attrac­
tive strategy for subgroups prone to this complication. 
This study demonstrated a low occurrence of bleeding 
at the puncture site after transradial PCI in patients 
hospitalized because of ACS. It was also observed that 
these events consisted only of small hematomas that 
did not require any medical intervention and sponta­
neously resolved, thus requiring no additional costs, 
procedures, or prolonged hospitalization. These patients 
received antiplatelet and antithrombotic medications, 
according to the routine of the institution, and the use 
of unfractionated heparin in the catheterization labo­
ratory (whether at full dose or not) did not affect the 
occurrence of bleeding, regardless of the recent use of 
enoxaparin at hospital admission.
The discussion regarding the superiority of particular 
antithrombin agents has long concerned the scope of PCIs, 
but different rates of periprocedural MACE have never 
Table 2 





(n = 66) P
Male gender, n (%) 55 (74.3) 47 (71.2) 0.68
Age, years 59.3 ± 9.9 60 ± 9.7 0.74
Systemic arterial hypertension, n (%) 66 (89.2) 52 (78.8) 0.09
Diabetes mellitus, n (%) 15 (20.3) 15 (22.7) 0.72
Dyslipidemia, n (%) 26 (35.1) 31 (47) 0.15
Smoking, n (%) 19 (25.7) 23 (34.8) 0.23
Chronic renal failure, n (%) 8 (10.8) 12 (18.2) 0.21
Left ventricular dysfunction, n (%) 29 (39.2) 35 (53) 0.1
Clinical presentation, n (%) 0.55
Unstable angina 25 (33.8) 20 (30.3)
ACS without ST­segment elevation 21 (28.3) 19 (28.8)
ACS with ST­segment elevation – primary PCI 9 (12.1) 14 (21.2)
ACS with ST­segment elevation – rescue PCI 7 (9.4) 3 (4.5)
ACS with ST­segment elevation – elective PCI 12 (16.2) 10 (15.1)
PCI, percutaneous coronary intervention; ACS, acute coronary syndrome.
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to 0.55; P = 0.0001). The reduction in the composite 
endpoint of death, AMI, and stroke was also significant 
(3.65% vs. 6.55%; OR = 0.56; 95% CI, 0.39 to 0.79; 
P = 0.01), and the analysis of the death outcome also 
showed benefits when using the radial access (OR 0.54; 
95% CI, 0.33 to 0.86; P = 0.01). A significant benefit 
was demonstrated when using the radial approach in this 
context, through the reduction of both post­procedural 
bleeding and ischemic complications.15 Notably, several 
studies have observed that bleeding complications are 
associated to an increased risk of MACE.16,17
The recent radial vs. femoral access for coronary 
intervention (RIVAL) study is the largest clinical in­
vestigation to date comparing the radial and femoral 
routes for coronary angiography and PCI. The RIVAL 
study was a randomized, multicenter, international study 
that included 7,021 patients and used outcomes such 
as death, AMI, stroke, and major bleeding unrelated 
to CABG surgery in 30 days. The primary outcome 
(combined events) was similar in both radial and 
femoral groups (3.7% vs. 4%; P = 0.50), but there was 
significant benefit for radial access in centers with a 
higher volume of procedures performed through this 
approach (relative risk [RR], 0.49; 95% CI, 0.28 to 0.87; 
P = 0.015)] and for patients with ACS with ST­segment 
elevation (RR, 0.60; 95% CI, 0.38 to 0.94; P = 0.026). 
Although similar rates of major bleeding unrelated to 
CABG in 30 days (0.7% vs. 0.9%; P = 0.23) have been 
reported, the radial group had a lower incidence of 
both local hematomas (RR, 0.40, 95% CI, 0.28 to 0.57; 
P = 0.0001) and pseudoaneurysm requiring occlusion 
(RR, 0.30; 95% CI, 0.13 to 0.71; P = 0.006).18
The authors believe that the greatest benefit of using 
the transradial access for PCI in ACS cases is the greater 
freedom in the use of antithrombotic drugs. Although 
this study did not have sufficient power to support the 
hypothesis, it is thought that it is possible to decrease 
the risk of bleeding complications by using the radial 
approach when performing crossover heparin therapy. 
study limitations
Although it provides important information on 
heparin management when using the transradial access 
in the daily routine of PCIs in Brazil, this study has 
limitations. The main limitation is the small sample size, 
which makes it impossible to confirm the equality of 
the bleeding rates between the groups. Furthermore, the 
study has a retrospective design, which may allow the 
selection of less complex patients for crossover heparin 
therapy by the interventional physician. Patients who 
used low­molecular­weight heparin < 12 hours after the 
crossover were not evaluated. Variables that may influ­
ence the bleeding risk, such as the number of treated 
vessels and time of procedure, were not compared. The 
GUSTO bleeding criteria were employed because this 
classification is easy and convenient to use, although 
it does not represent the ideal or most reliable model.
been demonstrated when comparing the use of unfractio­
nated heparin with that of low­molecular­weight heparin. 
Regarding vascular bleeding complications, conflicting 
results have been published in the literature comparing 
these two agents, with most studies reporting the reliability 
of dose­effect association, without the need for laboratory 
control, as the main advantage for low­molecular­weight 
heparin compared to unfractionated heparin.
However, crossover heparin therapy has been 
considered inappropriate in ACS since the publication 
of the SYNERGY trial, due to the higher frequency of 
bleeding complications without any benefits in terms 
of efficacy. In this study, there was no difference bet­
ween the unfractionated heparin and low­molecular­
weight heparin groups regarding the rate of death and 
AMI or regarding the composite endpoint of death 
or nonfatal AMI (14% vs. 14.5%). The rates of acute 
occlusion, failure, and emergency surgery were also 
similar. Although there was no difference in the rate 
of major bleeding determined by the GUSTO criteria 
(2.7% vs. 2.2%; P = 0.08), patients in the enoxaparin 
group had higher rates of major bleeding according to 
the TIMI criteria (9.1% vs. 7.6%; P = 0.008).10 Among 
the patients included in the SYNERGY trial, 47% (n = 
4,687) underwent PCI, and antithrombotic therapy was 
administered before randomization in 78% (n = 7,778). 
Despite the higher incidence of bleeding and need for 
transfusion in patients undergoing crossover, associa­
tion or causality could not be established, as these 
crossovers occurred after randomization. However, the 
crossover of heparin therapy has been discouraged by 
the guidelines.14
A recent meta­analysis compared the radial and femoral 
accesses in AMI and demonstrated a decrease of > 70% 
in the risk of major bleeding for the transradial approach 
relative to the femoral approach (0.77% vs. 2.61%; odds 
ratio [OR] 0.30; 95% confidence interval [95% CI]: 0.16 
Figure 1 – Comparison of the incidence of bleeding (mild, moderate, 
severe, and total) in groups A and B.
P = 0.37 P = 0.49 P = 0.88
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Group A
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In this study of patients with ACS with or without 
ST­segment elevation and treated through the radial 
approach, crossover heparin therapy was safe, with a 
low incidence of bleeding associated with the puncture 
site, and no increase in the incidence of other types 
of bleeding. There are no validated algorithms for 
crossover heparin therapy in ACS, but the crossover 
can be implemented without fear of bleeding at the 
radial puncture site when this is the route of choice.
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